Showing 7231-7240 of 8649 results for "".
- New Data Published from Phase 3 N-MOmentum Trial of Horizon's Uplinzahttps://modernod.com/news/new-data-from-phase-3-n-momentum-trial-of-horizons-uplinza-published/2481660/Horizon Therapeutics announced the publication of new data from the Phase 3 N-MOmentum pivotal trial of Uplinza. The data offer insights on serum biomarkers that signal acute attacks and disability worsening associated with NMOSD and illustrate the role of Uplinza in reducing these biom
- CoFi Raises $3.5 Million to Support Expansion of Its Multi-Party Payment Platform for Premium Elective Ophthalmic Surgerieshttps://modernod.com/news/cofi-raises-35-million-to-support-expansion-of-its-multi-party-payment-platform-for-premium-elective-ophthalmic-surgeries/2481656/CoFi announced it has closed a $3.5 million seed funding round to finance support of its current customer base as well as expansion into new eye are practices. “We are thrilled to close this funding round with investors who are strategically accretive to our business,”
- SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conferencehttps://modernod.com/news/sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference/2481654/With a goal to improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference taking place from June 9-11 in Manchester, England. Three-Year Myopia Control Eff
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy/2481648/EyePoint Pharmaceuticals announced it has completed enrollment in the phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential 9-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). “We are delighted to report the completion of enrollment in
- Gamesquare Partners with Vivior to Help Gamers Build Healthy Screen Habitshttps://modernod.com/news/gamesquare-partners-with-vivior-to-help-gamers-build-healthy-screen-habits/2481646/GameSquare Holdings announced a multi-year, multi-million dollar partnership with Swiss vision care startup Vivior with the aim of promoting healthy digital habits, according to a company news release. Through content creation, product development, and competition, GameSquare and Vivior
- NEI Explores Potential Impacts of Climate Change on Eye Healthhttps://modernod.com/news/nei-explores-potential-impacts-of-climate-change-on-eye-health/2481635/The National Eye Institute (NEI) convened a panel of experts on April 26, 2023, at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to discuss teye health care needs of the future, including the potential effects of a changing climate on eye health a
- Sight Sciences: Two Year Study Results Show Sustained Reductions in IOP and Glaucoma Medication Use with Omni Treatmenthttps://modernod.com/news/sight-sciences-two-year-study-results-show-sustained-reductions-in-iop-and-glaucoma-medication-use-in-mild-moderate-poag-patients-treated-with-omni/2481630/Sight Sciences announced the publication of 2-year results of the ROMEO (Retrospective, Observational, Multicenter, Evaluation of OMNI) study in Clinical Ophthalmology. The longest multicenter study of the Omni Surgical System technology to date in both standalone and comb
- NEI Scientists Publish Recipe for Making Blood Vessel Cells from Patient Stem Cellshttps://modernod.com/news/nei-scientists-publish-recipe-for-making-blood-vessel-cells-from-patient-stem-cells/2481626/Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. &ldquo
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development-1/2481623/Novel findings from researchers at the Brigham and Women's Hospital and Harvard Medical School, in collaboration with the Health Campus Göttingen in Germany, contradict previous notions about sugar's role in the onset of diabetic cataracts, according to a University Medical Center G&
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol